Verastem Oncology (NASDAQ: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...

In a report released today, Roger Song from Jefferies maintained a Buy rating on Kura Oncology (KURA – Research Report), with a price target of ...

V2X, Inc., , a leading provider of global mission solutions, will report fourth quarter and full year 2024 financial results on Monday, February 24, 2025, after market close. Senior management will ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Phosphoproteomics unveils the mode of action of clinical ATR inhibitors and explains their synergy with Gemcitabine in ...

The study’s lead researcher, Associate Professor Zhang Yongliang from the Department of Microbiology & Immunology at NUS ...

Study compares the antioxidant properties of Manuka honey (MH) and Ohia Lehua honey (OLH), revealing that MH contains ten ...

As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...

Pasithea Therapeutics opens European clinical trial sites and completes initial dosing of cohort 4: Miami Thursday, January 16, 2025, 12:00 Hrs [IST] Pasithea Therapeutics Corp., ...

Colorectal cancer (CRC) is a type of cancer that begins in the colon (large intestine) or rectum, which are parts of the digestive system.

Colorectal cancer (CRC) is a type of cancer that begins in the colon (large intestine) or rectum, which are parts of the ...

Boston, USA-based Verastem Oncology today announced the appointment of Matthew Ros as chief operating officer (COO). In his ...